Crossmark Global Holdings’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.16M | Buy |
13,510
+210
| +2% | +$18.4K | 0.02% | 588 |
|
|
2026
Q1 | $1.2M | Sell |
13,300
-116
| -0.9% | -$10.6K | 0.02% | 560 |
|
|
2025
Q4 | $1.21M | Buy |
13,416
+1,346
| +11% | +$128K | 0.02% | 551 |
|
|
2025
Q3 | $1.19M | Buy |
12,070
+8
| +0.1% | +$793 | 0.02% | 575 |
|
|
2025
Q2 | $1.1M | Sell |
12,062
-794
| -6% | -$76.8K | 0.02% | 581 |
|
|
2025
Q1 | $1.46M | Sell |
12,856
-241
| -2% | -$25.8K | 0.03% | 498 |
|
|
2024
Q4 | $1.38M | Sell |
13,097
-1,061
| -7% | -$114K | 0.03% | 485 |
|
|
2024
Q3 | $1.53M | Sell |
14,158
-64
| -0.5% | -$6.99K | 0.03% | 472 |
|
|
2024
Q2 | $1.54M | Sell |
14,222
-184
| -1% | -$21.7K | 0.03% | 465 |
|
|
2024
Q1 | $1.9M | Buy |
14,406
+441
| +3% | +$55.1K | 0.04% | 437 |
|
|
2023
Q4 | $1.7M | Sell |
13,965
-224
| -2% | -$25K | 0.04% | 448 |
|
|
2023
Q3 | $1.59M | Sell |
14,189
-680
| -5% | -$86.4K | 0.04% | 446 |
|
|
2023
Q2 | $2.07M | Buy |
14,869
+497
| +3% | +$67.5K | 0.04% | 405 |
|
|
2023
Q1 | $1.86M | Sell |
14,372
-236
| -2% | -$29.6K | 0.04% | 425 |
|
|
2022
Q4 | $1.86M | Buy |
14,608
+602
| +4% | +$69.9K | 0.05% | 409 |
|
|
2022
Q3 | $1.46M | Buy |
14,006
+91
| +0.7% | +$9.99K | 0.04% | 446 |
|
|
2022
Q2 | $1.46M | Buy |
13,915
+260
| +2% | +$30.8K | 0.04% | 467 |
|
|
2022
Q1 | $1.75M | Buy |
13,655
+219
| +2% | +$26.4K | 0.04% | 459 |
|
|
2021
Q4 | $1.66M | Sell |
13,436
-258
| -2% | -$33.8K | 0.04% | 482 |
|
|
2021
Q3 | $1.95M | Buy |
13,694
+342
| +3% | +$50.3K | 0.05% | 394 |
|
|
2021
Q2 | $2.08M | Buy |
13,352
+371
| +3% | +$60.1K | 0.05% | 364 |
|
|
2021
Q1 | $2.02M | Sell |
12,981
-237
| -2% | -$36.7K | 0.05% | 373 |
|
|
2020
Q4 | $1.98M | Sell |
13,218
-397
| -3% | -$56.1K | 0.05% | 376 |
|
|
2020
Q3 | $1.8M | Sell |
13,615
-927
| -6% | -$121K | 0.05% | 368 |
|
|
2020
Q2 | $1.69M | Buy |
14,542
+690
| +5% | +$79.5K | 0.05% | 377 |
|
|
2020
Q1 | $1.36M | Buy |
13,852
+113
| +0.8% | +$14.8K | 0.05% | 380 |
|
|
2019
Q4 | $2M | Sell |
13,739
-6,266
| -31% | -$865K | 0.05% | 371 |
|
|
2019
Q3 | $2.67M | Sell |
20,005
-576
| -3% | -$74.4K | 0.08% | 283 |
|
|
2019
Q2 | $2.35M | Sell |
20,581
-535
| -3% | -$62.7K | 0.07% | 331 |
|
|
2019
Q1 | $2.62M | Sell |
21,116
-163
| -0.8% | -$18.5K | 0.07% | 300 |
|
|
2018
Q4 | $2.14M | Buy |
21,279
+5,199
| +32% | +$585K | 0.07% | 335 |
|
|
2018
Q3 | $2.05M | Sell |
16,080
-1,043
| -6% | -$124K | 0.05% | 398 |
|
|
2018
Q2 | $1.85M | Sell |
17,123
-784
| -4% | -$85.3K | 0.05% | 415 |
|
|
2018
Q1 | $1.9M | Sell |
17,907
-1,626
| -8% | -$189K | 0.05% | 427 |
|
|
2017
Q4 | $2.29M | Buy |
19,533
+542
| +3% | +$61.3K | 0.06% | 391 |
|
|
2017
Q3 | $2.16M | Buy |
+18,991
| New | +$2.19M | 0.06% | 393 |
|
|
2016
Q3 | $2.16M | Buy |
+18,991
| New | +$2.35M | 0.06% | 393 |
|
Other funds holding ZBH
Crossmark Global Holdings's ZBH Position: Q2 2026 in Review
Crossmark Global Holdings increased its Zimmer Biomet (ZBH) stake by 1.6% in Q2 2026, buying an estimated $18.4K and bringing the position to 13,510 shares worth $1.16M. The position accounts for 0.02% of the portfolio, ranked #588.
Crossmark Global Holdings first reported a position in ZBH in Q3 2016 and has held it in 37 quarters since. The position peaked at $2.67M in Q3 2019. 906 funds tracked by Wall St. Rank hold ZBH as of Q2 2026.
- Crossmark Global Holdings held 13,510 shares of Zimmer Biomet worth $1.16M as of Q2 2026.
- Crossmark Global Holdings bought 210 Zimmer Biomet shares in Q2 2026, an estimated $18.4K.
- Zimmer Biomet made up 0.02% of Crossmark Global Holdings's portfolio in Q2 2026, its #588 holding.
- Crossmark Global Holdings first reported a position in Zimmer Biomet in Q3 2016 and has held it in 37 quarters since.
- Crossmark Global Holdings's Zimmer Biomet position peaked at $2.67M in Q3 2019.
- 906 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2026.
Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.